LRRC75A and neoplasm: Higher levels of post-cabozantinib LRRC75A expression were significantly associated with decreased relative shrinkage in tumor size (Figure 3A, p=0.004), while patients with partial response had significantly lower LRRC75A expression compared to those with stable disease (Figure 3B, p=0.011); there was not significant variation in LRRC75A expression based on rhabdoid versus sarcomatoid histology (Figure 3C).